08:49 AM EDT, 09/19/2024 (MT Newswires) -- Aethlon Medical ( AEMD ) said Thursday that the Medanta Institutional Ethics Committee has granted full ethics approval for its clinical trial of the Hemopurifier in cancer patients undergoing anti-PD-1 therapy.

The approval is valid for one year, followed by annual reviews.

The trial, which received a no objection certificate from Indian regulators, will be led by Dr. Ashok Vaid at Medanta Medicity Hospital in Gurugram, India, with treatments administered by Dr. Puneet Sodhi.

The company said the trial will assess safety, the number of Hemopurifier treatments needed, and their impact on extracellular vesicles concentrations and tumor cell targeting.

Aethlon shares were more than 5% higher in recent premarket trading.

Price: 0.3894, Change: +0.03, Percent Change: +8.65